7 Sources of evidence considered by the Committee
The Evidence Review Group (ERG) report for this appraisal was prepared by Warwick Evidence, University of Warwick:
-
Connock M, Cummins E, Shyangdan D et al. Abiraterone acetate for the treatment of metastatic, castrate‑resistant prostate cancer following previous cytotoxic chemotherapy, December 2011
The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist, patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist, patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.
Manufacturers or sponsors:
-
Janssen
Professional or specialist, and patient or carer groups:
-
British Association of Urological Surgeons
-
British Uro‑Oncology Group
-
Cancer Research UK
-
Macmillan Cancer Support
-
PCaSO – Prostate Cancer Network
-
Prostate Cancer Charity
-
Prostate Cancer Support Federation
-
Royal College of General Practitioners
-
Royal College of Nursing
-
Royal College of Physicians
-
United Kingdom Clinical Pharmacy Association
-
United Kingdom Oncology Nursing Society
Other consultees:
-
Department of Health
-
NHS Hertfordshire
-
NHS Bradford and Airedale
-
Welsh Government
Commentator organisations (did not provide written evidence and without the right of appeal):
-
British National Formulary
-
Commissioning Support Appraisals Service
-
Department of Health, Social Services and Public Safety for Northern Ireland
-
Healthcare Improvement Scotland
-
MRC Clinical Trials Unit
-
Prostate Action
The following individuals were selected from clinical specialist and patient expert nominations from the non‑manufacturer or sponsor consultees and commentators. They gave their expert personal view on abiraterone by attending the initial Committee discussion and providing written evidence to the Committee. They were invited to comment on the ACD.
-
Dr John Staffurth, nominated by the RCP on behalf of the NCRI, RCP, RCR, ACP, JCCO and the British Uro‑Oncology Group – clinical specialist
-
Dr Isabel Syndikus clinical expert, nominated by the RCP on behalf of the NCRI, RCP, RCR, ACP, JCCO – clinical specialist
-
Mr Hugh Gunn, nominated by the Prostate Cancer Federation – patient expert
-
Mr Stuart Watson, nominated by the Prostate Cancer Charity – patient expert
The following individuals were nominated as NHS Commissioning experts by the selected NHS trust allocated to this appraisal. They gave their expert or NHS commissioning personal view on abiraterone by attending the initial Committee discussion and providing written evidence to the Committee. They were invited to comment on the ACD.
-
Mrs Rasila Shah, nominated by NHS Hertfordshire – NHS Commissioning expert
Representatives from the following manufacturer or sponsor attended both Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.
-
Janssen